| Phase 15 trials |
|
Phase 1
|
NCT05497297 |
Aug → Oct 2022 |
impaired renal function disease |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06003088 |
Jun → Aug 2022 |
— |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04540016 |
Nov 2020 → Jan 2021 |
type 2 diabetes mellitus |
Sichuan Haisco Pharmaceutical Group Co., Ltd |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06084156 |
Aug → Dec 2019 |
type 2 diabetes mellitus |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05983289 |
May 2018 → Jul 2019 |
type 2 diabetes mellitus |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT06703268 |
Jan → Oct 2024 |
type 2 diabetes mellitus |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04727580 |
Mar 2021 → Jun 2022 |
glucose intolerance |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06059326 |
Jan → Nov 2019 |
type 2 diabetes mellitus |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT04564872 |
Nov 2020 → Jan 2022 |
type 2 diabetes mellitus |
Sichuan Haisco Pharmaceutical Group Co., Ltd |
Completed
|
No outcome recorded
|